Search results for

NPR's Adrian Ma and Wailin Wong, host of The Indicator podcast, join Rob Schmitz to discuss their favorite serious and less serious movies about money and the economy.

Wellness influencers tout the therapy's power for everything from rejuvenating skin and hair to boosting longevity. Devices sold for at-home use abound. We look at the evidence behind the hype.

Journalist Beth Gardiner says the fossil fuel industry is increasingly reliant upon plastic products. Her book is Plastic Inc.: The Secret History and Shocking Future of Big Oil's Biggest Bet.

NPR's A Martinez asks Dan Baer, former U.S. ambassador to the Organization for Security and Cooperation in Europe, about the Trump administration's recent rhetoric around NATO.

Insurance coverage of blockbuster obesity drugs has been spotty at best over the years, and it looks like things are getting worse, not better. Plans are dropping coverage or restricting it further.

As fuel protests bring Ireland to a standstill and UK leaders decry price hikes driven by the Iran war, Europe -- barely recovered from the energy shock of the Ukraine war -- faces another crisis.

The Orion crew module containing the four Artemis II astronauts splashed down in the Pacific Ocean Friday evening.

The Big Beautiful Bill Act sets aside special funding for rural health care, but the strings attached make it hard for them to continue some services, like dialysis.

President Trump said the U.S. would interdict vessels that had paid what he called an "illegal toll" to Iran to cross the Strait of Hormuz.

The Trump administration has said that enforcement of the FACE Act by the Biden DOJ represents "the prototypical example" of the weaponization of the law against conservatives.

The Army has launched an administrative review after two AH-64 Apache helicopters on a training run hovered near the hillside home of Kid Rock as the outspoken supporter of President Donald Trump saluted their crews.

A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs.